How to Cite
Abstract
References
Хмелевский Е.В., Миленин К.Н., Альбицкий И.А. Высокодозная внутритканевая лучевая терапия рака предстательной железы источниками 192Ir // Радиология - Практика. - 2008. — № 6. - C. 40-42.
Bracarda S., de Cobelli O., Greco C. et al. Cancer of the prostate // Crit Rev Oncol Haematol. - 2005. - Vol. 56. - P. 379-396.
D’Amico A.V., Whittington R., Malkowicz S.B. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer // JAMA. - 1998. - Vol. 280. - P. 969-974.
Demanes D.J., Martinez A.A., Ghilezan M. et al. Highdose-rate monotherapy: safe and effective brachutherapy for patients with localized prostate cancer // Int. J. Radiation Oncology Biol. Phys. — 2011. Vol. 78. — P. 1-7.
Fowler J., Chappell R., Ritter M. Is alpha/beta for prostate tumors really low? // Int J Radiat Oncol Biol Phys. - 2001. - Vol. 50. - P. 1021-1031.
Galalae R.M., Kovacs G., Schultze J. et al. Longterm outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-doserate brachytherapy for locally advanced prostate cancer // Int J Radiat Oncol Biol Phys. — 2002. — Vol. 52. — P. 81-90.
Gore J.L., Kwan L., Lee S.P., et al. Survivorship beyond convalescent: 48-months quality-of-life outcomes after treatment of localized prostate cancer // J Natl Cancer Inst-2009. — Vol. 101. — P. 888-892.
Gustafson G.S., Grills I., Huang R. et al. Comparing the effect of higher activity (source strength) of Ir-192 versus lower activity on toxicity and clinical outcomes of prostate high dose rate (HDR) brachytherapy (BT) // Int J Radiat Oncol Biol Phys. — 2002. — Vol. 54. (Suppl. 1). — P. 262.
Hoskin P.J., Bownes P.J., Ostler P. et al. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions // Radiother. Oncol. — 2003. — Vol. 6. — P. 285-288.
Hoskin P.J., Rojas A.M., Bownes P.J. et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer // Radioth. Oncol. — 2012. — Vol. 103. — P. 217-222.
Jereczek-Fossa B.A., Orecchia R. Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer // Radioth. Oncol. -2007. — Vol. 84. — P. 197-215.
Kovacs G., Potter R., Loch T. et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer // Radioth. Oncol. - 2005. — Vol. 74. — P. 137-148.
Kupelian P.A., Elshaikh M., Reddy C.A. et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large singleinstitution experience with radical prostatectomy and external-beam radiotherapy // J Clin Oncol. — 2002. — Vol. 20. — P. 3376-3385.
Martinez A.A., Gonzalez J., Ye H., Ghilezan M., Shetty S., Kernen K. et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose rate boost and external beam radiotherapy // Int J Radiat Oncol Biol Phys. — 2011. Vol. 79. — P. 363-370.
Mohhamed N., Kestin L., Ghilezan M. et al. Comparison odf acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer // Int J Radiat Oncol Biol Phys. — 2012. — Vol. 82. — P. 2004-2012.
Potters L., Kleinc E.A., Kattanb M.V. et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation // Radiother. Oncol. — 2004. — Vol. 71. — P. 29-33.
Robinson J.W., Moritz S., Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma // Int J Radiat Oncol Biol Phys. — 2002. — Vol. 54. — P. 1063-1068.
Vicini F.A., Vargas C., Edmundson G. et al. The role of high-dose rate brachytherapy in locally advanced prostate cancer // Semin. Radiat. Oncol. — 2003. — Vol. 13. — P. 98-108.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...